Carol L. Brosgart, M.D.

Clinical Professor of Medicine, Epidemiology and Biostatics, UCSF

Carol L. Brosgart, M.D., has served as a member of our board of directors since June 2021. Dr. Brosgart has extensive clinical, public policy, advocacy, and corporate experience having held senior management, board, and advisory positions in a number of settings. In addition to various advisory roles, Dr. Brosgart serves as an independent director on the boards of both public and privately held biotechnology companies (Galmed, Abivax, Enochian, and Intrivo Diagnostics) and previously served on the boards of Tobira and Juvaris, until their acquisitions. Dr. Brosgart’s senior management experience in biotechnology and healthcare included chief medical officer roles at Alios BioPharma and UCSF Benioff Children’s Hospital and Research Center and vice president, public health and policy at Gilead where she was responsible for the clinical development and approval of 2 antiviral therapies: Viread® for the treatment of HIV and Hepsera® for the treatment of chronic hepatitis B. Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, including clinical care, research, and teaching. Dr. Brosgart also is active in public policy through advocacy and advisory and board roles for numerous organizations and foundations, including the American Liver Foundation, the Hepatitis B Foundation, the SF AIDS Foundation, and Forum for Collaborative Research.

Trained as a pediatrician and in public health and preventive medicine, she was among the first physicians in the United States to recognize and treat patients with HIV/AIDS. Dr. Brosgart was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV/AIDS. Dr. Brosgart also served as senior advisor on science and policy to the Division of Viral Hepatitis at the Centers for Disease Control from 2011 to 2014.